CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo

Overview of attention for article published in Cancer Immunology, Immunotherapy, October 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter: 8 X users
patent: 6 patents

facebook: 1 Facebook page

Citations

dimensions_citation: 141 Dimensions

Readers on

mendeley: 131 Mendeley

Summary X Patents Facebook Dimensions citations

So far, Altmetric has seen 6 patents that reference this research output.

CXCR6-transduced T cells for targeted tumor therapy

Grant US-11723922-B2

United States of America

Compositions and methods for treating melanoma

Grant US-11633458-B2

United States of America

A CXCR3+ CELL OR CELL PREPARATION FOR USE IN CANCER TREATMENT

Application WO-2022152767-A3

World Intellectual Property Organisation (WIPO)

BLOOD-BASED PROTEIN BIOMARKER PANEL FOR EARLY AND ACCURATE DETECTION OF CANCER

Application WO-2022140576-A1

World Intellectual Property Organisation (WIPO)

T CELLS EXPRESSING CHEMOKINE RECEPTORS FOR TREATING CANCER

Application WO-2018152572-A1

World Intellectual Property Organisation (WIPO)

CXCR6-TRANSDUCED T CELLS FOR TARGETED TUMOR THERAPY

Application WO-2017064222-A1

World Intellectual Property Organisation (WIPO)